Global revenue from cancer treatments is set to reach $75 billion this year, a new report predicts.
Leading Anti-Cancer Drugs and Associated Market 2012-2022 estimates that overall revenues will increase strongly in the next decade due to emerging technologies and increasing demand.
An industry analyst at visiongain – who published the report – says there is an unmet need for “well targeted therapies with better safety and efficacy”.
The report predicts that Roche will continue to lead the oncology market throughout the study’s forecast period with its selection of brands.
Demand in both western and emerging markets also holds great promise as a global increase in cancer incidence and prevalence takes place.
New opportunities for treatments exist, the report says, with an increase in sales of small-molecule products and biological agents expected. Individual, personalised medicines will also benefit from unmet need.
Global sales in the submarkets of traditional antineoplastic agents, novel antineoplastic agents, hormone therapies, immunotherapies and other agents are also predicted in the study.
“Although oncology is one of the most researched areas of medicine, there remain un-met and under-met treatment needs,” the analyst said.
“There is a need for well targeted therapies with better safety and efficacy. It is crucial that anti-cancer drugs have minimal side effects, so that the quality of patients’ lives can be enhanced. Pharma companies will further explore this field, making therapeutic progress this decade. In particular, companion diagnostic tests with drugs will help in cancer treatment, giving more-personalised, better-targeted medicine.”